![Lisa Decker](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profile
Lisa L.
Decker formerly worked at UMass Chan Medical School, as Associate Director-Technology Licensing from 2000 to 2008, Chimerix, Inc., as Independent Director from 2023 to 2025, Nektar Therapeutics, as Vice President-Business Development from 2017 to 2019, Atreca, Inc., as Chief Business Officer from 2019 to 2021, and IGM Biosciences, Inc., as Chief Business Officer from 2021 to 2025.
Dr. Decker received her undergraduate degree from College of the Holy Cross (Massachusetts) and doctorate degree in 1998 from Tufts University School of Medicine.
Former positions of Lisa Decker
| Companies | Position | End |
|---|---|---|
| IGM BIOSCIENCES, INC. | Corporate Officer/Principal | 31/07/2025 |
| CHIMERIX, INC. | Director/Board Member | 20/04/2025 |
| ATRECA, INC. | Corporate Officer/Principal | 28/02/2021 |
| NEKTAR THERAPEUTICS | Corporate Officer/Principal | 31/05/2019 |
UMass Chan Medical School
 UMass Chan Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 31/07/2008 |
Training of Lisa Decker
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
43
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Nektar Therapeutics
 Nektar Therapeutics Pharmaceuticals: MajorHealth Technology Discovers and develops medicines in areas of high unmet medical need | Health Technology |
Chimerix, Inc.
 Chimerix, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for rare epilepsies, cancers and sleep disorders | Health Technology |
Atreca, Inc.
 Atreca, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops novel antibody-based immune therapeutics to treat a range of solid tumor cancers | Health Technology |
College of the Holy Cross (Massachusetts)
 College of the Holy Cross (Massachusetts) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UMass Chan Medical School
UMass Chan Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tufts University School of Medicine
 Tufts University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
IGM Biosciences, Inc.
 IGM Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops engineered IgM antibodies for the treatment of cancer patients | Health Technology |
- Stock Market
- Insiders
- Lisa Decker
